Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Contributed by: PR Newswire

Tags

HANSA-BIOPHARMA-Trial

More Like This

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease